NCT07206498View on ClinicalTrials.gov

A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

October 14, 2028

Study Completion Date

October 14, 2029

Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
DRUG

Osimertinib (Tagrisso®)

"Drug: Osimertinib Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples~Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI~Drug: Osimertinib Given PO, 80mg, once daily"

DRUG

WSD0922-FU

"Drug: WSD0922-FU Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples~Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI~Drug: WSD0922-FU Given PO"

Trial Locations (1)

200123

Shanghai East Hospital, Shanghai

All Listed Sponsors
lead

Wayshine Biopharm, Inc.

INDUSTRY

NCT07206498 - A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC | Biotech Hunter | Biotech Hunter